Sat, Aug 2, 2014, 5:09 AM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

NeurogesX, Inc. (NGSX) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • nomoneyhomeboy nomoneyhomeboy Jan 27, 2012 1:08 PM Flag

    Buy...Good DD Part III:

    -The company did not conduct the clinical trials the way that the FDA would have wanted them done. The studies were combined to show statistical significance.

    -The company met statistical significance on only one of the three endpoints even though the one was the most important in that it demonstrated efficacy (NPRS score).

    -Addressing a 30 min application (new) where the FDA might want to see more clinical data before granting approval.

    Thats a little worrisome, imo
    look what happen to cbrx

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Agree in your point of view. And it is important to anlyse all the positive and teh negative points.

      Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)this has "Priority Review", FDA Priority Review status is given to drug candidates that offer significant advances in treatment, or provide a treatment where no adequate therapy exists, and accelerates the standard review time from 10 months to six months, wich is the case.
      And note that NGX-4010 efficacy was superior to placebo regardless of sex, baseline pain score, or duration of neuropathy.


0.00470.0000(0.00%)Jul 31 9:55 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.